Zobrazeno 1 - 10
of 296
pro vyhledávání: '"J, Kuikka"'
Publikováno v:
Neuropediatrics. 42:207-209
A positive effect of fluoxetine has been shown in some children with autism. The present study was undertaken to correlate striatal dopamine transporter (DAT) binding and cerebrospinal fluid insulin-like growth factor-1 (CSF-IGF-1) with clinical resp
Publikováno v:
Duodecim; laaketieteellinen aikakauskirja. 116(4)
Publikováno v:
Duodecim; laaketieteellinen aikakauskirja. 116(4)
Publikováno v:
European Journal of Paediatric Neurology. 15:S23-S24
Publikováno v:
Clinical physiology (Oxford, England). 21(1)
Cardiotoxicity of anthracyclines is a clinical challenge in cancer chemotherapy. Limited data is available on the physiological mechanisms responsible for anthracycline-induced heart failure or its recovery. We studied four patients with a history of
Publikováno v:
European Neuropsychopharmacology. 20:S177-S178
Publikováno v:
Clinical physiology (Oxford, England). 20(5)
It is widely accepted that myocardial infarction results in adrenergic denervation of the infarcted and peri-infarcted myocardium. On the contrary, the concept of re-innervation of adrenergic nerve fibres is less well established. Although there is e
Autor:
E. Repo, Jyrki T. Kuikka, Kim A. Bergström, Jari Karhu, Jukka Hiltunen, Jari Tiihonen, J. Kuikka
Publikováno v:
Psychopharmacology. 147(3)
Rationale: Late onset type 1 alcoholism has been suggested to be associated with an underlying dopaminergic defect. Therefore, it is relevant to study both postsynaptic D2-receptor and presynaptic dopamine transporter (DAT) densities among alcoholics
Publikováno v:
Neuroscience. 83(2)
We investigated the effects of a single administration of tetrahydroaminoacridine (25 and 50 mg, orally), a cholinesterase inhibitor, on memory function in Alzheimer's disease patients. The recall of memory items from the end of the word list (recenc
Publikováno v:
Neuroscience letters. 195(1)
The present study investigated if acute treatment with tetrahydroaminoacridine (THA) (25 or 75 mg, p.o.) affects technetium-99m labelled ethylene dicysteinate (ECD) retention abnormalities in patients with mild to moderate Alzheimer's disease (AD; me